PMID- 18849613
OWN - NLM
STAT- MEDLINE
DCOM- 20090309
LR  - 20090216
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 148
IP  - 3
DP  - 2009
TI  - Immunoglobulin E-dependent regulation of the CCR3 chemokine receptor by 
      interferon-gamma in atopic asthmatics.
PG  - 219-27
LID - 10.1159/000161582 [doi]
AB  - BACKGROUND: The chemokine receptor CCR3 mediates the migration of cells that play 
      an important role in the pathogenesis of asthma to inflammatory foci. Interferon 
      (IFN)-gamma is known to downregulate the expression of some chemokine receptors. 
      Therefore, we decided to analyze the regulation of CCR3 by IFN-gamma in 
      asthmatics and to characterize the dependence of this process on immunoglobulin E 
      (IgE) levels. METHODS: Atopic asthmatics were treated with IFN-gamma or placebo, 
      and the IgE concentration in the blood was measured using an ultra-micro-ELISA 
      for total IgE. Mononuclear cells from patients and controls were isolated by 
      Ficoll-Hypaque gradient and incubated in the absence or presence of IFN-gamma for 
      different periods of time. After incubation, the cells were washed and lysed for 
      RT-PCR analysis, which was performed using a Perkin-Elmer kit. RESULTS: IFN-gamma 
      treatment apparently improved the evaluated clinical variables; however, the 
      differences were not significant compared to the placebo group. We found that 
      IFN-gamma downregulated CCR3 mRNA expression ex vivo and in vivo in those 
      patients with IgE levels higher than 500 IU/ml, whereas IFN-gamma upregulated 
      CCR3 mRNA expression in patients with IgE levels lower than 500 IU/ml. 
      Correspondence between ex vivo and in vivo results was observed using this 
      approach. There was found to be a direct correlation between total serum IgE and 
      CCR3 mRNA expression. CONCLUSIONS: In those asthmatic patients with high levels 
      of IgE, who are thus susceptible to downregulation of CCR3 by IFN-gamma, a 
      significant therapeutic effect with systemic IFN-gamma might be expected.
CI  - (c) 2008 S. Karger AG, Basel.
FAU - Garcia-Vega, Yanelda
AU  - Garcia-Vega Y
AD  - Centro de Investigaciones Biologicas, Clinical Trials Division, La Habana, Cuba.
FAU - Rodriguez-Perez, Judith
AU  - Rodriguez-Perez J
FAU - Bermudez-Badell, Cimara
AU  - Bermudez-Badell C
FAU - Blanco-Garces, Elizabeth
AU  - Blanco-Garces E
FAU - Valenzuela-Silva, Carmen
AU  - Valenzuela-Silva C
FAU - Lopez-Saura, Pedro
AU  - Lopez-Saura P
FAU - Bello-Rivero, Iraldo
AU  - Bello-Rivero I
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20081010
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (CCR3 protein, human)
RN  - 0 (Receptors, CCR3)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Asthma/blood/*drug therapy/genetics
MH  - Cells, Cultured
MH  - Double-Blind Method
MH  - Eosinophils/cytology/drug effects/metabolism
MH  - Female
MH  - Gene Expression Regulation/*drug effects
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Interferon-gamma/*pharmacology/therapeutic use
MH  - Leukocyte Count
MH  - Leukocytes, Mononuclear/cytology/drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/cytology/drug effects/metabolism
MH  - Receptors, CCR3/*genetics
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2008/10/14 09:00
MHDA- 2009/03/10 09:00
CRDT- 2008/10/14 09:00
PHST- 2007/08/06 00:00 [received]
PHST- 2008/04/23 00:00 [accepted]
PHST- 2008/10/14 09:00 [pubmed]
PHST- 2009/03/10 09:00 [medline]
PHST- 2008/10/14 09:00 [entrez]
AID - 000161582 [pii]
AID - 10.1159/000161582 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2009;148(3):219-27. doi: 10.1159/000161582. Epub 2008 
      Oct 10.